

Special Issue

Adjuvant Therapy and Neoadjuvant Therapy for Melanoma

Message from the Guest Editor

Adjuvant therapy and neoadjuvant therapy are two types of treatment used for melanoma, a type of skin cancer. Adjuvant therapy is used after primary treatment, such as surgery, to prevent the cancer from returning. It may involve chemotherapy, radiation therapy, or targeted therapy. Neoadjuvant therapy, on the other hand, is used before primary treatment in order to shrink the tumor and make it easier to remove. This may involve the same types of treatment as adjuvant therapy. Both adjuvant and neoadjuvant therapies have shown promising results in improving survival rates for patients with melanoma. This special issue will highlight clinical research on therapeutic strategies in melanoma.

Guest Editor

Dr. Michele Del Vecchio

Melanoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy

Deadline for manuscript submissions

closed (15 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/189306

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)